July 13, 2014 3:26 PM ET

Biotechnology

Company Overview of Syndax Pharmaceuticals, Inc.

Company Overview

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. Its lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute. Syndax Pharmaceuticals, Inc. was founded in 2005 and is...

400 Totten Pond Road

Suite 110

Waltham, MA 02451

United States

Founded in 2005

13 Employees

Phone:

781-419-1400

Fax:

781-419-1420

Key Executives for Syndax Pharmaceuticals, Inc.

Chief Executive Officer
Age: 62
Co-Founder and Chief Technology Officer
Age: 45
Co-Founder
Age: 57
Co-Founder and Advisor
Co-Founder
Compensation as of Fiscal Year 2014.

Syndax Pharmaceuticals, Inc. Key Developments

Syndax Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 12:30 PM

Syndax Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 12:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

Syndax Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 11:30 AM

Syndax Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 11:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Arlene M. Morris, Chief Executive Officer, President and Director, John S. Pallies, Chief Financial Officer and Treasurer, Peter Ordentlich, Co-Founder and Chief Technology Officer.

Syndax Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Syndax Pharmaceuticals, Inc. filed its S-1 on Mar 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
ITL Laboratories LLC United States
HuMab Solutions, Inc. United States
VasoGenix Pharmaceuticals, Inc. United States
RenovoRx, Inc. United States
Meridian Life Science, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 13, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Syndax Pharmaceuticals, Inc., please visit www.syndax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.